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Summary
 Background: It is believed that a local recurrence of a primitive breast cancer has the same prognostic factor 
profi le as its primary breast cancer tumor.
 Material/Methods: We compared the immunohistochemical expressions of the tumor suppressor protein p53, estro-
gen receptor (ER), c-erbB2, and E-cadherin in 57 primary invasive breast cancers and in their re-
spective LRs. The McNemar test and the kappa index were used for statistical analysis.
 Results: In 30 patients (52.6%) the expression of at least one of these markers was different between the 
primary and locally recurrent tumors. No signifi cant difference was observed between variations 
in the positive and negative expressions in the primary tumor and local recurrence in cerbB2 (ka-
ppa=0.86), E-cadherin (kappa=0.55), and p53 (kappa=0.7). However, the ER presented a low kap-
pa index (kappa=0.26, p>0.05).
 Conclusions: ER expression should be reviewed in local recurrent breast cancer. This relevant change in ER 
expression is likely to change the current clinical practice in breast cancer evaluation and treat-
ment.
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BACKGROUND
Breast cancer is the most common form of malignancy oc-
curring in women around the world. In 2003, more than 
41,610 new cases (46% of all cancer sites) were diagnosed 
and 9,335 deaths from breast cancer (10.4%) occurred in 
Brazil [1]. African American females have a higher mortal-
ity rate due to breast cancer [2]. Surgery is the main mo-
dality of the local treatment for breast cancer. On the other 
hand, many women will benefi t from hormone therapy. To 
choose the best adjuvant therapy, the tumor markers are an-
alyzed in the primary tumor for prognostic and predictive 
purposes. During the 1980’s, much work was done with as-
says on steroid receptor in breast cancer [3–7] . More recent-
ly, tumor markers were assessed by immunohistochemistry 
[6,8–10]. Some authors found a high concordance, rang-
ing from 71% to 85%, between estrogen receptor (ER) ex-
pression in primary breast carcinoma and its local, region-
al recurrence, or metastasis. Based on these works, some 
authors believe that the same profi le of the tumor marker 
in the primary tumor (PT) will be expressed in their local 
recurrence (LR) [3,4,10–13]. Therefore, the analysis of tu-
mor markers in ductal invasive breast cancer is not com-
monly reassessed in the LR.
Nevertheless, other authors found discordance between 
PTs and their metastatic recurrence [5–7]. This apparent-
ly contradiction could arise from the different methods of 
assessing tumor markers, i.e. cytosol assays or immunohisto-
chemistry, or due to the heterogeneity within a breast tumor 
mass. Variations in steroid receptor may result from tumor-
al subpopulations and/or differences in tumor cellularity 
of the cancer [14]. Most recent decisions for breast cancer 
treatment are based on prognostic and predictive factors. 
Among these tumor markers, p53, E-cadherin, estrogen re-
ceptor, and c-erbB2 have been used [13,15]. Estrogen recep-
tor, p53, and C-erbB2 are related to cell proliferation [16–
18], while E-cadherin is related to cell adhesion [19,20]. 
Four and 20% of primary tumors will have a local recur-
rence within 10 years [21].
After searching the literature (MEDLINE 1966–2004), only 
two small studies were found comparing the expression of 
estrogen receptor in the PT and in its LR, but in a small sam-
ple (6 and 14 cases) [3,11]. Others investigated the expres-
sions of estrogen and progesterone receptors, HER2/neu, 
and p53 in ductal carcinoma in situ treated with breast-con-
serving therapy (BCT) and in its local or distant recurrence 
[13]. These authors found some differences in the tumor 
markers expressed in the PT and its LR, although not sta-
tistically signifi cant.
To our knowledge, this is the fi rst study with a larger sam-
ple size to investigate tumor marker expression in PT and 
in its LR in invasive ductal carcinoma of the breast. If the 
LR changes its tumor marker expression, this work will be 
added to the literature that supports the results that have 
shown discordance between steroid receptor in the prima-
ry breast carcinoma and in its recurrence.
The aim of this study was to determine the expressions of 
p53, E-cadherin, estrogen receptor, and c-erbB2 in patients 
with primary breast cancer tumor and in its respective lo-
cal recurrence.
MATERIAL AND METHODS
Patients
Fifty-seven cases of histologically confi rmed local recur-
rence of invasive breast cancer diagnosed between 1995 
and 2000 were retrieved from the Instituto de Pesquisas Cito-
Oncológicas of Fundação Faculdade Federal de Ciências 
Médicas de Porto Alegre - Santa Casa de Misericórdia and 
from the Unity of Pathology of Hospital Nossa Senhora da 
Conceição. The respective paraffi n-embedded block with 
primary tumor f for each case was taken from the patholog-
ical archives for analysis. The inclusion criteria were age be-
tween 30 and 90 years, presence of invasive breast carcinoma, 
absence of signs of metastasis at diagnosis, had been submit-
ted to surgical treatment, and radiotherapy, chemotherapy 
or hormone therapy when indicated. The exclusion criteria 
were no invasive carcinoma, infl ammatory carcinoma, or the 
presence of carcinoma in the margins of the surgical resec-
tion. Tumor blocks from the PT and its LR were fi xed in for-
malin and embedded in paraffi n. All paraffi n blocks were 
reviewed by a pathologist (CGZ) to confi rm breast carcino-
ma according to the standard WHO Criteria [22].
Immunohistochemistry
All immunohistochemistry (IHC) assays were performed in 
a reference laboratory at the same time to reduce bias. The 
3-µm-thick tissue sections were put on organosilane slides. 
Five slides for each block were prepared: one for hematox-
ylin-eosin and four for IHC. The slides were incubated at 
60°C for 20 min for paraffi n removal. After that they were 
immersed for 10 min in xylol followed by 5 sequential ab-
solute alcohol immersions. For antigen retrieval, the slides 
were boiled in sodium citrate, pH 6, for 10 min in microwave. 
After reaching room temperature, the slides were rinsed for 
2×5 min in PBS (pH 7.2–7.8) and incubated in hydrogen 
peroxide at 3% for 10 min. Non-specifi c sites were blocked 
with horse normal serum diluted in PBS according to the 
manufacturer’s instructions (Dako A/S, Glostrup, Denmark). 
After non-specifi c blocking, the slides were rinsed in distilled 
water, followed by a 2×5 min PBS rinse. Primary antibodies 
were incubated according to the dilutions p53 (Dako D07) 
1: 400, E-cadherin (Santa Cruz G10) 1: 400, estrogen recep-
tor (DAKO 1D5) 1:2000, and C-erbB2 (DAKO polyclonal) 
1:4000. After 12 hours of overnight incubation in a humid 
chamber and a 2×5 min PBS rinse, the slides were incu-
bated with biotinylated rabbit-antimouse immunoglobulin 
(Ig) and biotinylated horseradish peroxidase streptavidin 
complex for detection of the primary antibody, according 
to the manufacture’s instructions (System LSAB2, Dako). 
The slides were counter-stained with hematoxylin, mount-
ed, and analyzed under an optical microscope.
All slides were submitted to rigorous standard methods 
and had positive and negative external controls, and estro-
gen receptor also had an internal positive control. Three 
different investigators (JLP, CGZ, and LM) evaluated all 
slides for immunostaining in a blind fashion. In case of 
disagreement, the slides were reviewed and a consensus 
view achieved. Positive expression for each tumor mark-
er was considered as follows: Estrogen Receptor (ER) and 
p53 – staining of more than 10% of the nuclei in high-pow-
er fi eld (HPF); E-cadherin and c-erbB2 – more than 10% 
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complete staining of the cell membranes in HPF. Tumors 
were considered c-erbB2 positive only if there was a clear 
brown cell membrane staining. The remaining tumors, in-
cluding those that showed a granular cytoplasmic staining, 
were considered to be c-erbB2 negative. The same criteri-
on was applied to E-cadherin. These values were based on 
previous studies [23–25].
Ethical issues and statistical analysis
This study was submitted to and approved by the Ethics Board 
of Irmandade Santa Casa de Misericórdia of Porto Alegre.
The McNemar test was based on matching the cases and 
it was used to compare the dichotomic values (positive/
negative) before and after treatment. The kappa index was 
used as a complementary method of reliability for the corre-
lation of the markers expressed on the PT and its LR. The 
kappa coeffi cient (?) measures pair-wise agreement among 
a set of category judgments, correcting for expected chance 
agreement. Values of kappa range from –1, for total disa-
greement, through 0, representing the agreement expect-
ed by chance, to +1 for perfect correlation. A kappa value 
of <0.20 indicates weak correlation, 0.21 to 0.40 fair, 0.41 
to 0.60 moderate, 0.61 to 0.80 good, and 0.81 to 1 excel-
lent correlation [26]. A signifi cant difference from zero in 
the value of kappa indicates similar samples, and likewise 
in the opposite case. EpiInfo-6 software (Center for Disease 
Control, Atlanta, USA) was used for data analysis.
RESULTS
This study is a retrospective analysis of 57 cases of histolog-
ically confi rmed local recurrent breast cancer diagnosed 
between 1995 and 2000. The paraffi n-embedded blocks of 
the respective PTs were retrieved from the pathological ar-
chives dated from 1990 to 2000. The immunohistochem-
ical expression of p53, estrogen receptor, c-erbB2, and E-
cadherin were analyzed in all paraffi n-embedded blocks in 
the same run. Interobserver and interassay variability were 
very low (kappa: 0.85). Clinical, laboratory, and pathologi-
cal fi ndings are summarized in Table 1. The mean time of 
disease-free survival was 32.5±24 months (mean ±SD). Of 
the 57 cases, 30 patients (52.6%) changed the expression 
of at least one tumor marker.
When the pair-wise analysis was performed, no difference 
was observed (McNemar p>0.05, Table 2). Nevertheless, a 
different scenario was observed with the kappa index. Table 
3 shows the immunohistochemical expressions of tumor 
markers in the PTs and in their LRs. Of the 27 negative ER 
expressions in the PT, 12 (44%) became positive in the LR, 
while of the 30 positive ER expressions in the PT, 9 (30%) 
became negative (kappa=0.25; p=0.051). p53, c-erbB2, and 
E-cadherin did not changed their expressions when the 
kappa index was used (p53=0.73; c-erbB2=0.86; E-cadher-
in=0.55; all p<0.001).
DISCUSSION
In theory, the LR should have the same profi le of tumor mark-
ers as the PT, since the LR is, by defi nition, the return of the 
Characteristics 
Age (years) mean (range) 50.7 (33–86)
Type of Surgery
Tumorectomy 30 (53%)
Radical modifi ed mastectomy 27 (47%)
Tumor
T1 15 (26%)
T2 30 (53%)
T3 12 (21%)
Axillary Status 
Positive 28 (53%)
Negative 25 (47%)
Histological type
Ductal Invasive Carcinoma (DIC) 42 (64%)
DIC with Extensive Intraductal Component 11 (19%)
Lobular Carcinoma  4 (7%)
Clinical Stage
I 11 (21%)
II 36 (68%)
III  6 (11%)
Disease-free Survival (months) mean (range) 32.5 (5–113)
Table 1. Characteristics of the patients. Table 2.  Tumor markers and immunohistochemistry expression in 
Primary Tumor (PT) and Local Recurrence (LR), pairing the 
samples. Values are numbers (percentages).
* MacNemar test.
Status PT (n=57) LR (n=57) P*
Estrogen Receptor
0.70Positive 30 (53) 33 (58)
Negative 27 (47) 24 (42)
p53 
Positive 17 (30) 13 (23)
0.52
Negative 40 (70) 44 (77)
cerbB2
Positive 29 (51) 25 (44)
0.57
Negative 28 (49) 32 (56)
E-cadherin
Positive 24 (42) 31 (54)
0.26
Negative 33 (58) 26 (46)
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same primitive tumor. The present study was conducted to 
confi rm such a hypothesis. All patients were submitted to ad-
equate treatment for breast cancer (i.e. surgery with safety 
margins free from neoplasia, being submitted to chemother-
apy, radiotherapy, and hormone therapy when indicated). 
Rigorous immunohistochemical procedures were followed 
to avoid artifacts. The expressions of prognostic and predic-
tive factors (ER and c-erbB2) and prognostic factors (p53 and 
E-cadherin) were analyzed in the PTs of breast cancer and 
in their LRs. Although small changes occurred in all tumor 
markers, the only instance in which 100% concordance be-
tween PT and LR was observed was when c-erbB2 was nega-
tive. As seen in Table 2, no difference was observed in all tu-
mor markers when the McNemar test was used (p>0.05). This 
is because no statistical difference was observed among the 
tumors that changed their expression from positive to nega-
tive and vice versa. This statistical method does not consider 
the individual cases that remained unchanged. Conversely, 
30 of the 57 patients (52.6%) changed the expression of the 
prognostic/predictive factor in some way, from positive to 
negative or vice versa. Such variation has a clinical signifi -
cance. To confi rm it statistically, we decided to use the kappa 
index, which considers these variations. The accuracy shown 
by the kappa index revealed a different scenario.
C-erbB2
C-erbB2 belongs to the family of epidermal growth factors 
(EGF) [18]. It is the main ontogeny that is activated in breast 
cancer and it is found in the mechanisms of tumor promo-
tion, resistance of disease to therapy, and vigilance of immuni-
ty in breast cancer. The c-erbB2 gene is located on the 17q21 
chromosome and its protein is expressed at low levels in the 
epithelial and myoepithelial tissue of normal breast cells. It 
is over-expressed in comedos, ductal carcinoma in situ, and 
in low levels in papillary and cribriform tumors in situ [18]. 
This protein is over-expressed in about 19% of breast tumors, 
thus refl ecting a poor prognosis [27]. Haffty et al. compared 
the over-expression of c-erbB2 in patients with breast cancer 
with local recurrence with controls without recurrence. He de-
scribed that a higher expression of c-erbB2 is more frequent 
in breast cancer with LR than c-erbB2 negative ones (56% vs. 
18%) in a 10-year follow-up [28]. This fi nding suggests that 
c-erbB2 expression is an important marker for LR.
Our data showed a 50.8% of incidence of c-erbB2 in the PT, 
similar to the 43.6% found by Bijker et al. [13], but higher 
than that found by Borg et al. [27]. Although different stages 
of breast cancer were analyzed, and a different criterion for 
positiveness for c-erbB2 was used, our kappa indexes were 
very similar to those found by Bijker et al. [13].
p53
p53 is a tumor-suppressing gene located on chromosome 
17p13.1 and is the most common single marker for genetic 
alterations in human tumors. Over 50% of human tumors 
show mutations in this gene. Loss of homozygosity of gene 
p53 is seen in virtually all cancers, particularly in lung, co-
lon, and breast cancers. This suggests that p53 serves as a 
guardian against the formation of cancer, preventing the 
propagation of cell genetic damage [29]. We verifi ed the 
mutant expression of this protein in our study. The inci-
dence of p53 was positive in 30% (17/57) of the PT and 
23% (13/57) of the LR, as shown in Table 2. Our fi ndings 
are in accordance with the data described in the literature, 
i.e. 20 and 40% for p53 in breast cancer [17].
E-cadherin
A loss or change in the substrate of cell adhesion and alter-
ation in cytoskeleton organization play important roles in 
the loss of differentiation. Moreover, these contribute to the 
formation of metastases: cell locomotion, proteolysis, surviv-
al, and proliferation in distant sites [20]. The mechanisms 
involved in breast cancer recurrence are still unknown. It 
is known that breast cancers at the same clinical stage show 
diverse clinical progression in different patients, independ-
ently of the therapeutic approach. It has been a challenge 
to identify the factors that will indicate the best therapeutic 
approach and follow-up according to its probable biological 
behavior [19]. E-cadherin expression was positive in 42% 
(24/57) of the PTs and in 54% (31/57) of the LRs when 
considered in the whole group (Table 2). These results are 
similar to those found by Yoshida et al. [30].
Estrogen receptor
By interacting with the ER, estrogen plays a central role in 
regulating the proliferation and differentiation of normal 
breast epithelium. During the past 20 years many studies 
have measured ER expression in breast cancer using bio-
chemical ligand-binding assays. These studies showed that 
approximately 60 to 70% express ER. Even a weak expres-
Tumor Marker A B C D kappa P
P53  12 (22)  39 (68)  5 (9)  1 (1.7) 0.73 <0.001*
cerbB2  25 (44)  28 (49)  4 (7)  0 0.86 <0.001*
E-cadherin  21 (37)  23 (40)  3 (5)  10 (18) 0.55 <0.001*
ER  21 (37)  15 (26)  9 (30)  12 (44) 0.25 0.051**
Table 3.  Expression of p53, cerbB2, E-cadherin, and Estrogen Receptor (ER) in the primary tumor (PT) and in its respective local recurrence (LR). 
Values are numbers of cases (percentages).
A: Both PT and LR are positives, no change in tumor marker expressions; B: Both PT and LR are negatives, no change in tumor marker expressions;
C: PT is positive and the LR became negative; D: PT is negative and the LR became positive;
* Concordance between the observations;
** Discordance between the observations.
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sion has a favorable prognostic factor [31,32] . Depending 
of the estrogen assay, a signifi cant difference can be found 
in the overall survival rate of women with mastectomy. 
Immunohistochemical assay of estrogen receptor alpha 
(irERalpha) seems to be a better prognosticator for the 5-
year follow-up than estrogen receptor in the cytosol [33]. 
As seen in Table 2, the ER signifi cantly changed either to 
positive or to negative expression in the local recurrence 
of the breast cancer. (kappa=0.25; p>0.05). These data are 
similar to the results found by Crawford et al, who used cy-
tosol assays [34], and by Li et al. [12], but different from 
those found by Bijker [13]. The possible reasons for this dis-
cordance could be due to the different criteria of positive-
ness for ER and due to the sample analyzed. We analyzed 
invasive ductal carcinoma, while Bijker et al. included only 
ductal in situ carcinoma. We chose to consider an expres-
sion positive when >10% of nuclei were stained, because 
it seems to correlate well with enzyme immunoassay [23]. 
Conversely, Bijker et al. considered any staining as positive. 
This criteria has a low specifi city (34%) [9].
Another possibility could be related to receptor heteroge-
neity in different areas of the tumor [14]. It is important to 
note that the assessment of staining of ER is a diffi cult area 
in terms of concordance of the results [35]. Unlike the cy-
tosol assay, where a numerical result is produced, evalua-
tion of staining is subjective. So far there is no agreement 
to the best way to assess the staining, nor what the cut-off 
should be [9]. Hawkins states that no single mode of expres-
sion was entirely satisfactory, and the probability of a good 
“out-come” (prognosis or response to endocrine therapy) 
increased with increasing activity (either fmol ER sites/mg 
protein or percentage of cells staining for ER). Thus the use 
of a single “cut-off” should be avoided and activity quanti-
fi ed, or stratifi ed into categories [36].
Despite these differences, it is expected that some changes in 
ER expression happen. However, it should be noted that in a 
signifi cant number of cases a major change in ER expression 
from the PT to the LR has occurred (Table 3). These fi ndings 
lead us to believe that LR may mutate their receptors due to 
different types of cancer treatment, such as radio or chemo-
therapy [4,34] , or to the heterogeneity of the tumor [14].
Prophylactic hormone treatment (tamoxifen and similar 
drugs) is considered mainly for ER-positive tumors, since 
it leads to an increase in overall survival and disease-free 
time. In those tumors that have been reliably shown to be 
ER-negative, adjuvant tamoxifen remains a matter for re-
search. However, some years of adjuvant tamoxifen treat-
ment substantially improves the 10-year survival of wom-
en with ER-positive tumors and of women with tumors of 
unknown ER status; the proportional reductions in breast 
cancer recurrence and mortality appear to be largely unaf-
fected by other patient characteristics or treatments. This 
new expression of ER would explain the reduction of breast 
cancer recurrence in tumors with unknown ER status or 
with unreliable assessment of ER status. For the purpose of 
a patient’s treatment, it is not so relevant to defi ne if it is 
an occurrence of a new neoplasm, or a loss of differentia-
tion features, referred to as ‘dedifferentiation’, or the het-
erogeneity of the tumor. Our data shows that the local re-
currence has a change in it markers. Although our sample 
has a moderate size, a change of more than 50% in tumor 
marker expressions seems to be a clinically relevant issue. 
Therefore, the tumor markers should be reassessed, espe-
cially those prognostic factors with a predictive value, here 
represented by ER and c-erbB2.
CONCLUSIONS
No signifi cant change was observed in the expressions of 
cerbB2, E-cadherin, and p53 in PT and LR. Nevertheless, a 
signifi cant change in the expression of estrogen receptor 
in the PT and its LR was observed in this group of patients 
with breast cancer. This variation suggests the need for re-
valuation of the estrogen receptor, independent of its re-
sult in the primary tumor.
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